| Morel M Belk, CRNA | |
|
9601 Interstate 630 Exit 7, Little Rock, AR 72205-7202 | |
| (501) 202-2093 | |
| Not Available |
| Full Name | Morel M Belk |
|---|---|
| Gender | Female |
| Speciality | Certified Registered Nurse Anesthetist (crna) |
| Experience | 22 Years |
| Location | 9601 Interstate 630 Exit 7, Little Rock, Arkansas |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1407951502 | NPI | - | NPPES |
| 148796701 | Medicaid | AR |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207L00000X | Anesthesiology | C01390 (Arkansas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Baptist Health Medical Center-little Rock | Little rock, AR | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Arkansas Health Group | 7911802079 | 541 |
News Archive
Approximately 10 percent of the general population take a proton pump inhibitor (PPI) drug to block stomach acid secretions and relieve symptoms of frequent heartburn, acid reflux and gastroesophageal reflux disease.
Astute Medical, Inc. today hailed the launch of a collaborative global initiative calling for the elimination of preventable deaths from acute kidney injury (AKI) by 2025. The Company cited the publication of a new Commission from The Lancet and the International Society of Nephrology, along with the release of results from the 0by25 AKI "Global Snapshot" study, as key steps forward in the effort to reduce the global burden of AKI.
Working with a line of highly metastatic head and neck cancer cells, a research team at the Winship Cancer Institute and Emory University School of Medicine has found that a specific cell surface receptor present at very low levels in non-metastatic head and neck cancer cells.
YM BioSciences Inc., today announced that two posters have been accepted for presentation at the American Association for Cancer Research (AACR) Annual Meeting to be held from April 17-21 in Washington, DC. The first poster describes the results of the previously reported collaboration with researchers at the University of Toronto for the development of highly potent antibody-radionuclide conjugates for use in the treatment of cancer. The poster will describe activity of 111In-NLS-nimotuzumab against breast cancer cells with high and low EGFR expression.
HTMS, an Emdeon company, is pleased to introduce Alfred™. Alfred is an algorithm-based analytics model that can help all types of healthcare stakeholders calculate health plan rates and federal subsidies through its comparison and advisory capabilities and is both easy to use and understand.
› Verified 5 days ago
| Entity Name | Arkansas Health Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1508800962 PECOS PAC ID: 7911802079 Enrollment ID: O20040331000754 |
News Archive
Approximately 10 percent of the general population take a proton pump inhibitor (PPI) drug to block stomach acid secretions and relieve symptoms of frequent heartburn, acid reflux and gastroesophageal reflux disease.
Astute Medical, Inc. today hailed the launch of a collaborative global initiative calling for the elimination of preventable deaths from acute kidney injury (AKI) by 2025. The Company cited the publication of a new Commission from The Lancet and the International Society of Nephrology, along with the release of results from the 0by25 AKI "Global Snapshot" study, as key steps forward in the effort to reduce the global burden of AKI.
Working with a line of highly metastatic head and neck cancer cells, a research team at the Winship Cancer Institute and Emory University School of Medicine has found that a specific cell surface receptor present at very low levels in non-metastatic head and neck cancer cells.
YM BioSciences Inc., today announced that two posters have been accepted for presentation at the American Association for Cancer Research (AACR) Annual Meeting to be held from April 17-21 in Washington, DC. The first poster describes the results of the previously reported collaboration with researchers at the University of Toronto for the development of highly potent antibody-radionuclide conjugates for use in the treatment of cancer. The poster will describe activity of 111In-NLS-nimotuzumab against breast cancer cells with high and low EGFR expression.
HTMS, an Emdeon company, is pleased to introduce Alfred™. Alfred is an algorithm-based analytics model that can help all types of healthcare stakeholders calculate health plan rates and federal subsidies through its comparison and advisory capabilities and is both easy to use and understand.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Morel M Belk, CRNA 11001 Executive Center Dr, Suite 200, Little Rock, AR 72211-4316 Ph: () - | Morel M Belk, CRNA 9601 Interstate 630 Exit 7, Little Rock, AR 72205-7202 Ph: (501) 202-2093 |
News Archive
Approximately 10 percent of the general population take a proton pump inhibitor (PPI) drug to block stomach acid secretions and relieve symptoms of frequent heartburn, acid reflux and gastroesophageal reflux disease.
Astute Medical, Inc. today hailed the launch of a collaborative global initiative calling for the elimination of preventable deaths from acute kidney injury (AKI) by 2025. The Company cited the publication of a new Commission from The Lancet and the International Society of Nephrology, along with the release of results from the 0by25 AKI "Global Snapshot" study, as key steps forward in the effort to reduce the global burden of AKI.
Working with a line of highly metastatic head and neck cancer cells, a research team at the Winship Cancer Institute and Emory University School of Medicine has found that a specific cell surface receptor present at very low levels in non-metastatic head and neck cancer cells.
YM BioSciences Inc., today announced that two posters have been accepted for presentation at the American Association for Cancer Research (AACR) Annual Meeting to be held from April 17-21 in Washington, DC. The first poster describes the results of the previously reported collaboration with researchers at the University of Toronto for the development of highly potent antibody-radionuclide conjugates for use in the treatment of cancer. The poster will describe activity of 111In-NLS-nimotuzumab against breast cancer cells with high and low EGFR expression.
HTMS, an Emdeon company, is pleased to introduce Alfred™. Alfred is an algorithm-based analytics model that can help all types of healthcare stakeholders calculate health plan rates and federal subsidies through its comparison and advisory capabilities and is both easy to use and understand.
› Verified 5 days ago
Faber A White, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 1701 S Shackleford Rd, Little Rock, AR 72211 Phone: 501-219-7481 | |
Louis W Sessions, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 9601 Interstate 630 Exit 7, Little Rock, AR 72205 Phone: 501-202-2093 | |
David M Dean, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 9601 Interstate 630 Exit 7, Little Rock, AR 72205 Phone: 501-202-2093 | |
Ken Wade, CRNA Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 9601 Interstate 630 Exit 7, Little Rock, AR 72205 Phone: 501-202-2093 | |
Garry Jones, M.D. Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 500 S University Ave, Suite 505, Little Rock, AR 72205 Phone: 501-664-4532 Fax: 501-663-4335 | |
Mrs. Tatiana Puntarelli, MD Anesthesiology Medicare: Medicare Enrolled Practice Location: 1 Childrens Way # 203, Little Rock, AR 72202 Phone: 501-364-1100 Fax: 501-364-4082 | |
Gregory Ryan Mehaffey, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 4301 W Markham St # 783, Little Rock, AR 72205 Phone: 501-686-8000 |